ArticleInternational journal of chronic obstructive pulmonary disease2026
Routine Blood Biomarkers and Lung Function in Asthma-COPD Overlap versus Asthma-Only Among Hospitalized Asthma Patients: A Retrospective Cross-Sectional Study.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare routine blood biomarkers, lung function, and medication-associated biomarker patterns between hospitalized asthma patients classified as having asthma-COPD overlap (ACO) and those with asthma-only. Methods: This retrospective cross-sectional analysis included 505 hospitalized asthma patients admitted between January 2020 and December 2024, comprising 190 with ACO and 315 with asthma-only. Disease history, pulmonary function parameters, complete blood cell counts, differential percentages, immunoglobulin E, and medication exposure were extracted from electronic medical records and analyzed using complete cases. Multivariable logistic regression, multivariable linear regression, Spearman correlation, and receiver operating characteristic (ROC) analyses were used to evaluate associations and discriminatory performance. Medication analyses were exploratory because treatment was not randomized. Results: Compared with asthma-only patients, patients with ACO were older, had a lower prevalence of allergy history, used inhaled corticosteroids, long-acting beta2-agonists, and long-acting muscarinic antagonists more frequently, and had worse airflow limitation and lower diffusing capacity. Higher neutrophil percentage (adjusted odds ratio: 2.15, 95% confidence interval: 1.62-2.85, p<0.001) and lower lymphocyte percentage (adjusted odds ratio: 0.51, 95% confidence interval: 0.39-0.67, p<0.001) were independently associated with ACO after Bonferroni correction. In ACO patients, inhaled corticosteroid and long-acting beta2-agonist exposure was nominally associated with higher neutrophil-related and lower lymphocyte-related measures, but these observational findings should not be interpreted as treatment effects. FEV1/FVC showed the best discrimination for ACO (area under the curve [AUC]: 0.696), whereas neutrophil percentage showed modest complementary discrimination (AUC: 0.596). Conclusion: Within this hospitalized asthma cohort, ACO was associated with older age, more severe airflow limitation, impaired diffusing capacity, and a more neutrophil-dominant systemic inflammatory profile than asthma-only. Routine blood biomarkers, particularly neutrophil and lymphocyte percentages, may complement pulmonary function parameters in identifying ACO, but their standalone diagnostic performance was modest. Medication-associated biomarker differences were exploratory and require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.